ESMO BREAST 2026
LUMINAL
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
Efficacy of inavolisib (INAVO) + palbociclib (PALBO) +
fulvestrant (FULV) in patients (pts) with PIK3CA-mutated,
hormone receptor-positive, HER2-negative (HER2-),
endocrine-resistant advanced breast cancer (aBC) with and
without hyperglycaemia (HG) in the Phase III INAVO120 trial
420RO
Emergence of ESR1 mutations (ESR1m) in ctDNA during
first-line (1L) endocrine-based therapy in HR+/HER2_
advanced breast cancer: Findings from the SERENA-6
trial
419RO
Capivasertib (C) and fulvestrant (F) for patients (pts) with
HR+/HER2_ advanced breast cancer (ABC): final overall
survival (OS) results from the Phase 3 CAPItello-291 trial
417O
A window-of-opportunity (WOO) trial of giredestrant +/-
LHRH analogue vs anastrozole + LHRHa in
premenopausal patients with ER+/HER2- early breast
cancer: PREcoopERA
LBA2
ctDNA detection rates during surveillance in high-risk
HR+/HER2 negative breast cancer from the TRAK-ER study
1O